Page 5 - Pharma Sector

Pharma market grows 8.7% in August; cardiac and anti-diabetic segments lead

The Indian Pharma Market grew 8.7% in August 2025, with the cardiac, anti-diabetic, and anti-neoplastic segments driving growth. Sun Pharma maintained its leadership position

Glenmark Pharma up 3% on DCGI nod to start phase 3 trial of Envafolimab

Around 11:20 PM, Glenmark Pharmaceuticals shares continued to trade higher, up 3.05 per cent at ₹2,051.40 per share. In comparison, BSE Sensex was trading 0.25 per cent lower at 80,518.51 levels.

Pharma stock up 37% in 6 mths; Nuvama initiates with 'Buy', eyes 29% gains

According to Nuvama analysts Shrikant Akolkar, Aashita Jain and Gaurav Lakhotia, the company is positioned for robust growth over the medium-term, driven by capacity expansion and product additions.

Health ministry looks to reduce drug development, approval timelines

The Union Health Ministry has proposed amendments to NDCT Rules 2019 to reduce test licence timelines from 90 to 45 days and ease approvals for BA/BE studies

Trump plans hefty tax on imported drugs, risking higher prices, shortages

President Donald Trump has plastered tariffs on products from almost every country on earth. He's targeted specific imports, including autos, steel and aluminium. But he isn't done yet. Trump has promised to impose hefty import taxes on pharmaceuticals, a category of products he's largely spared in his trade war. For decades, in fact, imported medicine has mostly been allowed to enter the United States duty-free. That's starting to change. US and European leaders recently detailed a trade deal that includes a 15 per cent tariff rate on some European goods brought into the United States, including pharmaceuticals. Trump is threatening duties of 200 per cent more on drugs made elsewhere. Shock and awe' is how Maytee Pereira of the tax and consulting firm PwC describes Trump's plans for drugmakers. This is an industry that's going from zero (tariffs) to the potential of 200 per cent.' Trump has promised Americans he'll lower their drug costs. But imposing stiff pharmaceutical tariffs

Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has secured UK MHRA approval for its trastuzumab biosimilar Dazublys, used in HER2-positive breast and gastric cancer treatment

US pharma tariffs unlikely to hit Indian drugmakers materially: Ind-Ra

Ind-Ra said US tariffs may cause only short-term pricing impact for Indian pharma as firms remain fortified by diversification, strong balance sheets, and global market positioning

Turbocharging India: Assuming global economic leadership

Higher tariffs could render many Indian products uncompetitive in US markets and bring unfavourable repercussions to the domestic economy

Automobiles to pharma & healthcare: India Inc earnings stay in slow lane

Corporate profits remained weak in Q1FY26, amid single-digit growth in revenues for the ninth consecutive quarter

Shilpa Medicare share jumps 4% on 1:1 bonus issue; check record date here

Shilpa Medicare shares rose after the company announced a 1:1 bonus issue, with the Board approving the proposal in its meeting on August 13, 2025.

Mounjaro KwikPen by Lilly debuts in India at ₹14,000 for diabetes, obesity

Eli Lilly has launched its Mounjaro KwikPen in India at ₹14,000 for the 2.5 mg dose; the once-weekly injector targets diabetes and obesity, competing with Wegovy

Chemists urge crackdown on instant online delivery of high-risk medicines

Chemists' body urges action against e-pharmacies, quick commerce apps for delivering high-risk drugs without checks, warning of rising misuse and youth addiction

Pfizer share price up 3% on rolling out this vaccine; key details inside

Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India.

Pharma Inc mulls offshore strategy as US tariff fears hit sentiment

Despite current exemptions, Indian pharma firms are preparing for potential US tariffs through offshore units, EU market focus, and sourcing diversification

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

The impact on innovator contract research, development and manufacturing organisations (CRDMOs) would be relatively lower

Ozempic maker's plight shows why managing markets matter for pharma giants

Novo's shares plunged amid rising competition, missed expectations, and governance issues, exposing the risks of neglecting market sentiment in high-growth pharma bets

India launches formal rules to fix, streamline drug and device clearances

India has issued first official guidelines for expert panels to bring consistency, speed, and transparency to drug and device approvals amid a broader regulatory overhaul

Indoco Remedies rises 6% on EU GMP certificate, trims gains after Q1 show

Indoco Remedies announced that it has received a Certificate of EU GMP Compliance from the European Health Authorities for its sterile drug product manufacturing facility at Goa Plant II.

Dr Reddy's Laboratories Q1 print misses target; brokerages split on outlook

Dr Reddy's Laboratories' posted a revenue of ₹8,545.2 crore, up 11 per cent year-on-year (Y-o-Y) but flat sequentially.

Results preview: Pharma firms stare at muted earnings growth for Q1

Indian pharma firms are set to post modest Q1FY26 earnings, with Revlimid erosion impacting US revenues and domestic growth moderating in chronic therapies